Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... widely used as a navigational tool in vehicles from ... vehicle on three axes to evaluate its exact position ... School of Physical Engineering is now scaling down this ... and more futuristic technologies. Working in collaboration with ...
... 5 Regenicin™, Inc. (OTC Bulletin Board: ... announced today that Mr. Christopher A. Hadsall, whose primary ... to join the company as Chief Operating Officer.  Mr. ... Regenicin™ and will be instrumental in working with various ...
... MiMedx Group, Inc. (OTC Bulletin Board: ... patent protected biomaterial-based products, announced today that its results ... be released before the opening of the market on ... live broadcast of its third quarter conference call on ...
Cached Biology Technology:A tracking device that fits on the head of a pin 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 3MiMedx Group, Inc. Announces Release Date For Third Quarter Results 2
(Date:4/23/2014)... of Toronto Scarborough research shows that male black widow ... a rare example of mate preference by male ... post-doc Emily MacLeod and Maydianne Andrade, a professor in ... field studies and the wild that males overwhelmingly chose ... male black widows can tell whether a potential mate ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23, 2014) People who ... little potential to restore neurological function. However, a study ... future issue of Cell Transplantation , but is ... at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one ... stem cells (PBSCs) injected directly into the brain and ...
(Date:4/23/2014)... boom has transformed the energy landscape in the ... cause conflict among the energy industry, residents and ... They add that degraded water quality is a ... feature article appears in the ACS journal ... Mauter and colleagues point out that a major ...
Breaking Biology News(10 mins):Picky male black widow spiders prefer well-fed virgins 2Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2
... scientist Dr. Gadi V.P. Reddy is concerned about ... health of island residents and ecosystems. He has ... use and has recently been awarded an $188,000 ... (USDA-NIFA) Pest Management Alternatives Program (PMAP). Dr. Monte ...
... PA, June 24, 2011 Adolescents who diet and ... behaviors and binge eating) carry these unhealthy practices into ... by University of Minnesota researchers and published in the ... American Dietetic Association . "The findings from the ...
... applications in reconstructive and cosmetic surgery and in the food ... prolines within the protein need to be hydroxylated. BioMed Central,s ... the first time the α1 chain of type 1 collagen ... hydroxylation to human collagen. Most collagen used is derived ...
Cached Biology News:UOG scientist wins USDA competitive funding 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 3
Assay Diluent, 10 L...
Assay Diluent Trial Pack, 4 x 100 mL...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
Biology Products: